Repligen (NASDAQ:RGEN) Releases FY 2025 Earnings Guidance

Repligen (NASDAQ:RGEN) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 1.670-1.760 for the period, compared to the consensus earnings per share estimate of 1.710. The company issued revenue guidance of $685.0 million-$710.0 million, compared to the consensus revenue estimate of $692.8 million.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on RGEN. TD Cowen started coverage on shares of Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 price target for the company. Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Wolfe Research began coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. Finally, HC Wainwright reduced their price target on shares of Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus target price of $182.91.

Repligen Stock Performance

RGEN traded up $9.72 during trading on Thursday, hitting $160.45. 836,138 shares of the company traded hands, compared to its average volume of 573,573. The firm has a market cap of $8.99 billion, a P/E ratio of -432.67, a price-to-earnings-growth ratio of 4.08 and a beta of 0.99. The stock’s fifty day moving average is $155.04 and its 200 day moving average is $148.71. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a one year low of $113.50 and a one year high of $203.13.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. As a group, equities analysts predict that Repligen will post 1.54 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.